myelodysplastic syndromes
Showing NaN - NaN of 51
MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Feb 16, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia Trial in Tampa (Fludarabine, Melphalan, Total
Active, not recruiting
- Acute Myeloid Leukemia
- +17 more
- Fludarabine
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023
MDS Trial in Worldwide (Magrolimab, Azacitidine, Placebo)
Active, not recruiting
- Myelodysplastic Syndromes
- Magrolimab
- +2 more
-
Birmingham, Alabama
- +168 more
Dec 7, 2022
MDS Trial in Tampa (Canakinumab Injection, Darbepoetin Alfa)
Recruiting
- Myelodysplastic Syndromes
- Canakinumab Injection
- Darbepoetin Alfa
-
Tampa, FloridaMoffitt Cancer Center
Nov 21, 2022
MDS, Secondary Acute Myeloid Leukemia Trial in Tampa (CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes,
Recruiting
- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia
- CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
- Standard of Care Chemotherapy
-
Tampa, FloridaMoffitt Cancer Center
Sep 27, 2022
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)
Completed
- Myelodysplastic Syndromes
- +2 more
-
Birmingham, Alabama
- +58 more
Aug 24, 2022
MDS Trial in Worldwide (Oral Azacitidine, Durvalumab)
Active, not recruiting
- Myelodysplastic Syndromes
- Oral Azacitidine
- Durvalumab
-
New Haven, Connecticut
- +65 more
Aug 19, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Busulfan
- +11 more
-
Duarte, California
- +26 more
Aug 11, 2022
MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)
Terminated
- MDS
- Myelodysplastic Syndromes
- APR-548 + Azacitidine
-
Tampa, Florida
- +3 more
Jul 20, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (Azacitidine, Durvalumab)
Active, not recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Azacitidine
- Durvalumab
-
New Haven, Connecticut
- +94 more
Jun 9, 2022
Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (H3B-8800 (RVT-2001))
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- H3B-8800 (RVT-2001)
-
Stanford, California
- +26 more
Mar 23, 2022
MDS Trial in Worldwide (Luspatercept, Placebo)
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia Trial in Tampa (drug, radiation, procedure)
Completed
- Non-Hodgkin's Lymphoma
- +7 more
- Fludarabine
- +7 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Sep 14, 2021
MDS Trial in Tampa (cenersen, Dexamethasone)
Terminated
- Myelodysplastic Syndromes
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Feb 18, 2021
MDS Trial in Canada, United States (anti-thymocyte globulin)
Completed
- Myelodysplastic Syndromes
- anti-thymocyte globulin
-
Washington, District of Columbia
- +27 more
Jan 24, 2021
MDS Trial in Germany, United States (Best Supportive Care, BI 836858)
Terminated
- Myelodysplastic Syndromes
- Best Supportive Care
- BI 836858
-
Jacksonville, Florida
- +4 more
Dec 18, 2020
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Tumors Trial in Tampa (busulfan,
Completed
- Chronic Myeloproliferative Disorders
- +4 more
- busulfan
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute at Universit
Dec 9, 2020
Quality of Life in Older vs. Younger Adult Patients Undergoing
Completed
- Myelodysplastic Syndromes
- Hematopoietic Cell Transplant
- ePRO survey
-
Stanford, California
- +5 more
Nov 30, 2020
MDS Trial in United States (ARRY-614, p38/Tie2 inhibitor; oral)
Completed
- Myelodysplastic Syndromes
- ARRY-614, p38/Tie2 inhibitor; oral
-
Tampa, Florida
- +3 more
Sep 4, 2020